Rijnstate Ziekenhuis Stichting — Clinical Trial Site

163 Registered trials

81 Currently recruiting

Organisation

Rijnstate Ziekenhuis Stichting

Location

Arnhem, Netherlands

Identifier

ORG-100021667

Address

Wagnerlaan 55, 6815 AD, Netherlands

Departments

-
#2915:Cardiology
#3714: Cardiology
2401: Medical oncology
3021: Neurology
3714: Cardiology
4001: Cardiology
Afd. Inwendige geneeskunde
Afdeling interne Geneeskunde
Cardiologie
Cardiology
Cardiology Department
chirurgie
Department of Haematology-Internal Medicine
Department of Medical Oncology
Department of Neurology
Department of Pulmonary Medicine
Dept. of Internal Medicine
Emergency Department
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and hepatology
Gynaecologie
Gynaecology
Hematology
Intensive Care
Intensive care unit
Internal Medicine
Internal Medicine, Vascular Medicine
Interne geneeskunde
Internist
Longgeneeskunde
Longgeneeskunde (longziekten)
Lung
Lung Diseases
MDL
Medical oncology
Medische Oncologie
N/A
NA
Nephrology
Neurologie
Neurology
NLD004:Pulmonology
Nuclear Medicine
Oncology
Oncology center
Oncology department
Orthopaedics
orthopedic surgery
Paediatric Gastroenterology
Paediatrics
Pediatrics
Pneumology
Poli Lung diseases
Psychiatry
Pulmanory Medicine Department
Pulmonary Science
Pulmonology
radiologie en nucleaire geneeskunde
Reproductive medicine and gynecology
Research Facility
Rheumatology
Rijnstate Ziekenhuis Stichting
stomach liver intestine department
Surgery
Trialbureau KCHL
urology
Vasculair geneeskunde
Vascular Centre
Vascular medicine
Ward (Internal Medicine)
Ziekenhuis Rijnstate

Clinical trials at this site (163)

Search interface

SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD) Pending

2023-510312-40-00 Secondary hyperparathyroidism 6
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 urothelial cancer 11
Ultrasound-guided Radiofrequency Ablation versus radioactive Iodine as treatment for Hyperthyroidism caused by Solitary Autonomous Thyroid N… Pending

2024-515602-34-01 Hyperactive thyroid nodules 11
RESET-TRD; a Randomised trial on oral ESketamine compared to Electroconvulsive Therapy for patients with Treatment Resistant Depression Pending

2024-517485-42-00 Non-psychotic therapy resistant unipolar depression 5
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Chronic Kidney Disease 4
A clinical study investigating modafinil for the treatment of severe fatigue in patients with inflammatory bowel disease (MODIFI-IBD trial) Pending

2026-525163-41-00 Inflammatory bowel disease 10
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2… Recruiting

2025-521936-12-00 Adults with Type 2 Diabetes and/or Metabolic Syndrome 5 2026-04-24
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting

2024-520433-76-00 Newly Diagnosed Multiple Myeloma 4 2026-01-08
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
T3-4-Hypo trial Recruiting

2024-513883-24-00 Hypothyroidism Triiodothyronine Quality of Life Persist 5 2025-11-02
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Acute Myeloid Leukemia (AML) 5 2025-08-05
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo… Recruiting

2024-517410-15-01 Rectal cancer 5 2025-01-14
The QUEEN-IVF trial: Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open-label, randomized crossover pi… Recruiting

2024-511190-30-00 Short-coupled Idiopathic Ventricular Fibrillation 4 2024-11-25
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting

2022-501105-12-00 Urothelial Carcinoma 5 2024-07-15
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06